Introducing VDAC1’s N-terminal into cells was shown to inhibit both Bcl-2’s and Bcl-XL’s anti-apoptotic function, illustrating that VDAC1 could be a target for anti-cancer drugs (54, 71–73). Here, BCL2 is linked to cancer.